We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
“[We] need to ensure that our ports are adequately staffed and equipped to deal with this problem—and right now that’s simply not the case,” said Sen. Claire McCaskill (D-Mo.). Read More
U.S. officials seized more than 12 tons of illicit opioids at ports of entry between 2013 and 2017, according to a new report that bolsters FDA Commissioner Scott Gottlieb’s call for more international mail facility staff to stem the addiction epidemic. Read More
Orphan drug development takes 18 percent longer to reach the product launch stage than new drugs across the board, according to a new analysis from the Tufts Center for the Study of Drug Development. Read More
An FDA advisory committee voted 12 to 8 Thursday that Akcea Therapeutics’ NDA for treatment of a rare genetic disease demonstrated safety and efficacy. Read More
As part of its increased focus on drug compounding, the FDA issued a final guidance clarifying the term “outsourcing facility” and detailing requirements for compounders operating under 503A that are next to an outsourcing facility. Read More
The most frequent defendants included Teva Pharmaceuticals and Teva Pharmaceutical Industries at 73 and 45 cases, respectively, Mylan at 46 cases and Apotex at 44 cases. Read More
Australia’s Therapeutic Goods Administration revised its guidelines for confidentiality obligations and conflicts of interest for members of advisory committees, overhauling the guidance with major content and structural changes. Read More
Ahead of an anticipated speech on drug pricing by President Trump on Friday, a group of House Democrats spelled out their own list of actions needed to deal with the problem. Read More